Kolon TissueGene unveiled 17-year long-term safety data for TG-C (Invossa) at OARSI, confirming zero tumor cases in 219 patients and efficacy in obese patients with BMI over 30.
Kolon TissueGene Confirms 17-Year Safety of TG-C, Efficacy in Obese Patients
Source: 서울경제
Read Full Story →
